- Home
- ROIV vs RYAAY Comparison
ROIV vs RYAAY Comparison
Compare ROIV & RYAAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | RYAAY |
|---|---|---|
| Founded | 2014 | 1985 |
| Country | United Kingdom | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Air Freight/Delivery Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7B | 28.5B |
| IPO Year | 2021 | 2003 |
Fundamental Metrics
Financial Performance| Metric | ROIV | RYAAY |
|---|---|---|
| Price | $35.43 | $54.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 6 |
| Target Price | $48.08 | ★ $67.52 |
| AVG Volume (30 Days) | ★ 6.0M | 1.5M |
| Earning Date | 11-09-2026 | 11-02-2026 |
| Dividend Yield | N/A | ★ 1.40% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,260,000.00 | N/A |
| Revenue This Year | $530.75 | $2.38 |
| Revenue Next Year | $685.92 | $8.96 |
| P/E Ratio | ★ N/A | $12.60 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.99 | $51.68 |
| 52 Week High | $42.50 | $74.24 |
Technical Indicators
Market Signals| Indicator | ROIV | RYAAY |
|---|---|---|
| Relative Strength Index (RSI) | 43.66 | 44.60 |
| Support Level | $33.15 | $53.45 |
| Resistance Level | $35.70 | $56.14 |
| Average True Range (ATR) | 1.14 | 1.12 |
| MACD | -0.34 | 0.09 |
| Stochastic Oscillator | 35.90 | 34.91 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About RYAAY Ryanair Holdings plc
Ryanair is Europe's largest low-cost airline, known for its extensive network and highly efficient business model. Operating over 3,600 daily flights across more than 220 airports in 36 countries, Ryanair has built its success on offering affordable air travel while maintaining tight control over costs. The airline primarily uses Boeing 737 aircraft, including the newer 737 8-200 "Gamechanger" variant, which simplifies operations and reduces expenses. Ryanair focuses on high passenger volume, ancillary revenue, and operational efficiency, ensuring its position as a leading airline in Europe.